Pharmaceutical reactivation of p53 pathways in cancer

Current Pharmaceutical Design

Volumn 17, Issue 6, 2011, Pages 534-535

  Azmi, Asfar S ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PROTEIN P73;

CANCER CHEMOTHERAPY; CANCER GENE THERAPY; DRUG MECHANISM; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; GENES, P53; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79953654935     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (7)

1. Crawford LV, Pim DC, Gurney EG, Goodfellow P, Taylor-Papadimitriou J. Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein. Proc Natl Acad Sci USA 1981; 78(1): 41-5.
2. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9(12): 862-73.
3. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8(1): 25-37.
4. Eischen CM, Lozano G. p53 and MDM2: antagonists or partners in crime? Cancer Cell 2009; 15(3): 161-2.
5. Chene P. Targeting p53 in cancer. Curr Med Chem Anticancer Agents 2001; 1(2): 151-61.
6. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13(1): 23-31.
7. Ruffner H, Bauer A, Bouwmeester T. Human protein-protein interaction networks and the value for drug discovery. Drug Discov Today 2007; 12(17-18): 709-16.